Accéder au contenu
Merck

Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma.

Cancer cell (2006-05-16)
Richard Smith, Leah A Owen, Deborah J Trem, Jenny S Wong, Jennifer S Whangbo, Todd R Golub, Stephen L Lessnick
RÉSUMÉ

Our understanding of Ewing's sarcoma development mediated by the EWS/FLI fusion protein has been limited by a lack of knowledge regarding the tumor cell of origin. To circumvent this, we analyzed the function of EWS/FLI in Ewing's sarcoma itself. By combining retroviral-mediated RNA interference with reexpression studies, we show that ongoing EWS/FLI expression is required for the tumorigenic phenotype of Ewing's sarcoma. We used this system to define the full complement of EWS/FLI-regulated genes in Ewing's sarcoma. Functional analysis revealed that NKX2.2 is an EWS/FLI-regulated gene that is necessary for oncogenic transformation in this tumor. Thus, we developed a highly validated transcriptional profile for the EWS/FLI fusion protein and identified a critical target gene in Ewing's sarcoma development.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
NKX2.2 (EP336) Rabbit Monoclonal Primary Antibody